In an interview with PharmaShots, Dr. David Kendall, Senior Global Medical Advisor at Zealand Pharma shared his views on the availability of Zegalogue in the US for severe hypoglycemia in […]readmore
Tags : Zealand Pharma
In an interview with PharmaShots, Emmanuel Dulac, Pharm.D., Ph.D., President and CEO of Zealand Pharma shares insight on the US FDA’s approval of Zegalogue and its availability in both an auto-injector […]readmore
Shots: The approval is based on efficacy results from P-III studies involve assessing Zegalogue vs PBO in children aged 6-17yrs. and in adults with T1D The study met its 1EPs […]readmore
1. Epizyme Reports the US FDA Acceptance of NDA for Tazverik (tazemetostat) to Treat Follicular Lymphoma Published: Feb 14, 2020 | Tags: Epizyme, Reports, US, FDA, Acceptance, NDA, Tazverik, tazemetostat, Follicular […]readmore
Shots: Valeritas to sell all its business to Zealand, in an all-cash transaction of ~$23M. Zealand will continue Valeritas’ commercially-focused operations and retain nearly all its employees For the smooth […]readmore
1.Roche’s Tecentriq + Chemotherapy Receives EC’s Approval as 1L Treatment for Extensive Stage Small Cell Lung Cancer Published: Sept 06, 2019 | Tags: Roche, Tecentriq, Chemotherapy, Receives, EC, Approval, Initial Treatment, […]readmore
Shots: The advancement of BI 456906 to P-II study is based on the safety and tolerability and a wt. loss in individuals with a BMI up to 40 kg/m2 , […]readmore